Get the Stockscreener App
2.47
6.93%
0.16
After Hours:
2.48
0.010
+0.40%
Sangamo Therapeutics Inc stock is traded at $2.47, with a volume of 13.47M.
It is up +6.93% in the last 24 hours and up +26.67% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$2.31
Open:
$2.3
24h Volume:
13.47M
Relative Volume:
1.66
Market Cap:
$515.36M
Revenue:
$176.23M
Net Income/Loss:
$-257.83M
P/E Ratio:
-1.7034
EPS:
-1.45
Net Cash Flow:
$-246.00M
1W Performance:
+20.49%
1M Performance:
+26.67%
6M Performance:
+448.28%
1Y Performance:
+581.57%
1-Day Range:
$2.2501
$2.53
1-Week Range:
$2.042
$2.84
52-Week Range:
$0.304
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
2.47 | 515.36M | 176.23M | -257.83M | -246.00M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Astellas and Sangamo sign capsid deal for neurological diseases - MSN
Astellas partners with Sangamo on cutting-edge gene therapy - The Pharma Letter
Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development (NASDAQ:SGMO) - Seeking Alpha
Sangamo and Astellas link up in a $1.32B AAV deal - BioWorld Online
HC Wainwright Reiterates Buy Rating for Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Shares Gap UpHere's What Happened - MarketBeat
Sangamo stock gains on Astellas licensing deal (SGMO:NASDAQ) - Seeking Alpha
Sangamo inks $20M gene therapy deal with Astellas; shares rally - Investing.com
Sangamo Shares Rally Premarket on License Deal With Astellas - MarketWatch
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Astellas hopes Sangamo's capsid can get gene therapies across the blood-brain barrier - FirstWord Pharma
Regarding Sangamo - substack.com
Sangamo Therapeutics, Inc. and Astellas Pharma Inc. Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases - Marketscreener.com
Sangamo Therapeutics Lands Major $1.3B Gene Therapy Deal with Astellas for Brain Disease Treatment - StockTitan
Sangamo Therapeutics (NASDAQ:SGMO) Shares Down 5%Time to Sell? - MarketBeat
Sangamo surges 24% after Roche ends development of hemophilia A gene therapy - MSN
Sangamo Therapeutics (NASDAQ:SGMO) Shares Gap DownShould You Sell? - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Upgraded by StockNews.com - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Trading Up 25.5%Still a Buy? - MarketBeat
Sangamo shares surge on Roche gene therapy withdrawal By Investing.com - Investing.com Canada
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces hurdles - Investing.com
Sangamo Therapeutics (NASDAQ:SGMO) Upgraded to "Buy" at Truist Financial - MarketBeat
The Analyst Landscape: 6 Takes On Sangamo Therapeutics - Benzinga
Sangamo Biosciences’ Legal Victory and Hemophilia Trial Success - TipRanks
Jacobs Levy Equity Management Inc. Lowers Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.
Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30% - Simply Wall St
Sangamo Therapeutics (NASDAQ:SGMO) Downgraded to Hold Rating by StockNews.com - MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Sold by Wasatch Advisors LP - MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update - MarketBeat
GSA Capital Partners LLP Sells 587,544 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat
Sangamo stock climbs 12% post-market on FDA update for ST-503 - MSN
Drug developer stocks slide further in fall, despite gains from Exelixis and Xencor - BioWorld Online
Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts - Simply Wall St
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain - BioSpace
Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment - Marketscreener.com
Sangamo's Novel Gene Therapy for Chronic Pain Gets FDA Clearance for Clinical Trials | SGMO Stock News - StockTitan
What is HC Wainwright's Forecast for SGMO FY2024 Earnings? - MarketBeat
FY2028 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays - MarketBeat
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces challenges, opportunities - Investing.com Canada
Sangamo: Q3 Earnings Snapshot - Marketscreener.com
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates - MSN
Earnings call: Sangamo Therapeutics reports progress in gene therapies By Investing.com - Investing.com Australia
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Sangamo Therapeutics reports progress in gene therapies - Investing.com India
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):